Compare Adaptive Biotechnologies Corp (ADPT) vs Fortinet Inc (FTNT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Fortinet Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20 (market cap $3.33B), while Fortinet Inc trades at $156.92 (market cap $116.25B). The key difference: Fortinet Inc is far larger — about 34.9× Adaptive Biotechnologies Corp's market cap, and Fortinet Inc is trading nearer its 52-week high, Adaptive Biotechnologies Corp nearer its low. Which is the better fit depends on your goals.
| ADPT | FTNT | |
|---|---|---|
Market Cap | $3.33B | $116.25B |
Sector | Health | Technology |
52-Week High | $22.37 | $162.35 |
52-Week Low | $10.24 | $74.39 |
Enterprise Value | $3.19B | $113.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Fortinet (FTNT) trades at $158.67, up 1.55% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with revenue growing to $6.80B in 2025 and net income of $1.85B, though valuation multiples like P/E of 62.93 appear elevated. Recent earnings have consistently beaten expectations, and the company maintains robust profitability with a gross margin of 80.3%. News highlights include AI-driven security growth and upcoming Q2 2026 results announcement on July 29, 2026.
The outlook remains positive due to strong execution and cybersecurity demand, but high valuation and competitive pressures pose risks. Analyst consensus is mixed with a $115.53 price target below current levels, suggesting caution despite bullish technicals. Key risks include execution missteps and market volatility, while institutional sentiment leans neutral with 47.06% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →
